Although the time to hematopoietic recovery and incidence of acute and chronic GVHD are influenced by graft type,18, 19 the optimal use of G‐CSF and timing of its initiation following allogeneic HCT for AML remain unclear. Here, CSF3 is linked to graft versus host disease.